Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

RECOMMENDED

Radio-Oncology

A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease

doi: 10.1007/s00345-018-2551-9.

LeukemiaMyeloproliferative Neoplasms (MPNs)

Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy

Ann Hematol.

Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, Kündgen A, Gattermann N, Aul C, Kondakci M, Kobbe G, Haas R, Germing U

doi: 10.1007/s00277-018-3466-7.

Phase 3 Safety Study of Intravenous NEPA, a Novel Fixed Antiemetic Combination of Fosnetupitant and Palonosetron in Patients Receiving Highly Emetogenic Chemotherapy

Ann Oncol.

Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M

doi: 10.1093/annonc/mdy169.

Sarcoma

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Lancet Oncol.

Bisogno G, De Salvo GL, Bergeron C, Gallego Melcón S, Merks JH, Kelsey A, Martelli H, Minard-Colin V, Orbach D, Glosli H, Chisholm J, Casanova M, Zanetti I, Devalck C, Ben-Arush M, Mudry P, Ferman S, Jenney M, Ferrari A, European paediatric Soft tissue sarcoma Study Group.

doi: 10.1016/S1470-2045(19)30617-5.

Further Publications

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Cochrane Database Syst Rev.

Rutjes AW, Porreca E, Candeloro M, Valeriani E, Di Nisio M

doi: 10.1002/14651858.CD008500.pub5.

Lung, Respiratory and Thoracic Cancer

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

JAMA Oncol.

Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ

doi: 10.1001/jamaoncol.2020.4232.

Leukemia

An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy

Clin Cancer Res.

Wang Y, Cai YY, Herold T, Nie RC, Zhang Y, Gale RP, Metzeler KH, Zeng Y, Wang SQ, Pan XY, Yang TH, Wu YB, Zhang Q, Wuxiao ZJ, Du X, Liang ZW, Su YZ, Xu JB, Wang YQ, Liu ZL, Wu JW, Zhang X, Wu BY, Xiao RZ, Wang SB, Li JY, Chi PD, Zhang QY, Chen SL, Qin ZY, Zhang XM, Zhong N, Hiddemann W, Liu QF, Zhang B, Liang Y

doi: 10.1158/1078-0432.CCR-20-3417.

Non-Malignant Blood Disorders

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

Lancet Haematol

Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A

doi: 10.1016/S2352-3026(20)30373-2

Related content